Altimmune Inc ALT
News
Roche obesity-pill trial results weigh on shares of Eli Lilly, Novo Nordisk
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT
Altimmune's stock pops as analysts see obesity-drug partnership potential
Altimmune's stock soars more than 40% after biopharma company says trial of obesity drug led to weight loss
Altimmune Gets FDA Fast-Track Designation for Pemvidutide in NASH